組織培養研究

論文

THE CHARACTERIZATION OF HUMAN BONE MARROW STROMA CELLS IN RELATION TO THEIR DIFFERENTIATION INTO SEROTONIN-PRODUCING NEURAL CELLS

Nobuhiko MARUNOUCHI, Toshimasa SAKAKIBARA, Mahito OHKUMA, Eiichi MIYAC ...

2007 年 26 巻 4 号 p. 171-183
発行日: 2007年
公開日: 2008/03/13

DOIhttps://doi.org/10.11418/jtca.26.171

ジャーナルフリー

抄録を表示する抄録を非表示にする

Bone marrow stroma cells (MSCs) have been shown to differentiate into multiple lineages and have great potential for regenerative therapy. We have obtained hMSCs from 6 human adults. They were all positive for CD13, CD44, and CD90 and weakly positive for CD49, while negative for CD45, suggesting that they were different from hematopoetic stem cells. hMSCs were induced to become neuronal cells and maintained as long as three weeks in the serum free medium supplemented with N2. An increase in the amount of mRNA was observed for the NeuroD1, neurofilament M and H, MAP2, neuron-specific enolase, tryptophan hydroxylase, Nurr1, and neuron specific Na⁺ channel genes, and the existence of voltage-gated Na⁺ channels that were sensitive to tetrodotoxin was confirmed electro physiologically. These results suggested that hMSCs differentiated into serotonergic neural cells. However, the expression of genes specific for stroma cells, the Big-h3 and vimentin-genes, was observed equally during the induction process, indicating that the expression pattern was not the completely same as in genuine neural cells. hMSCs cultured with serial passages showed aging phenomena at the cellular level under the various conditions examined in this study. Trials to isolate cellular clones proliferating indefinitely have not succeeded.

抄録全体を表示

PDF形式でダウンロード (1206K)
マウス脂肪由来培養細胞から軟骨細胞への分化誘導

石村大輔, 山本直樹, 田島香里, 鷲見大輔, 山本康洋, 赤松浩彦, 松永佳世子, 山田治基

2007 年 26 巻 4 号 p. 185-192
発行日: 2007年
公開日: 2008/03/13

DOIhttps://doi.org/10.11418/jtca.26.185

ジャーナルフリー

抄録を表示する抄録を非表示にする

マウス皮下脂肪組織から分離・培養した脂肪組織由来培養細胞（Adipose-derived stromal vascular fraction culture cells: ADSVFs）に対して、細胞表面マーカーの解析を行ったところ、間葉系幹細胞マーカーの CD１０５陽性率は６５．１±５．０％であった。次に ADSVFs を用いて凝集培養法による軟骨細胞への分化誘導を検討したところ、培養開始時に２×１０^５ cell/ml 以上の ADSVFs を用いることで軟骨細胞マーカーの aggrecan の mRNA が検出された。さらに ADSVFs から CD１０５陽性の脂肪由来組織幹細胞（Adipose-derived stem cells: ASCs）を選択・分離し、細胞凝集法とアテロコラーゲンゲル培養法による軟骨細胞への分化誘導を検討した結果、Non sort の ADSVFs よりも CD１０５陽性細胞から軟骨細胞へ分化誘導した方が、aggrecan の mRNA が多く検出された。また、CD１０５陽性細胞をアテロコラーゲンゲル培養法にて分化誘導した場合、細胞凝集法とほぼ同程度の aggrecan の mRNA を発現する細胞に分化させることができた。軟骨組織の再生医療を想定した場合、軟骨細胞をゲルシート状に培養し、欠損部に適した形状に加工することが必要であると考えられるため、さらに詳細な検討を継続する必要がある。

抄録全体を表示

PDF形式でダウンロード (1053K)
SENSITIZATION OF HUMAN CANCER CELLS TO ANTI-CANCER DRUGS BY LEAF EXTRACT OF ASHWAGANDHA (LASH)

Kamaljit KAUR, Nashi WIDODO, Avinash NAGPAL, Sunil C KAUL, Renu WADHWA

2007 年 26 巻 4 号 p. 193-199
発行日: 2007年
公開日: 2008/03/13

DOIhttps://doi.org/10.11418/jtca.26.193

ジャーナルフリー

抄録を表示する抄録を非表示にする

Medicinal value of Withania somnifera Dunal (Ashwagandha) extends from anti-inflammatory, antiseptic, anti-stress, anti-arthritic, anti-rheumatic, anti-bronchitis, immuno- and appetite- stimulator to promote overall memory, rejuvenation, vitality, endurance, stamina and longevity. However, the molecular biology of myriads of these anti-disease or health-promoting effects remains insufficiently explored to date. We earlier reported that the Leaf extract from Ashwagandha (Lash) has selective anticancer activity that operates through the activation of p53 tumor suppressor pathway. Here we report that the selective killing activity of Lash can be employed in combination with anticancer drugs to yield an effective combinatorial anticancer formulation.

抄録全体を表示

PDF形式でダウンロード (669K)

J-STAGEへの登録はこちら（無料）